Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRINASDAQ:KTTAOTCMKTS:PARNFNASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.61-5.8%$0.69$0.54▼$2.22$6.14M0.29935,726 shs46,872 shsKTTAPasithea Therapeutics$0.75-3.4%$1.10$0.71▼$7.50$5.77M0.332.07 million shs299,809 shsPARNFParnell Pharmaceuticals$0.08$0.08$0.05▼$0.35N/A26.33N/AN/APLRZPolyrizon$0.73-3.9%$48.63$0.55▼$1,200.00$4.04MN/A7.58 million shs300,495 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera-5.83%-7.13%-5.28%-28.84%-38.80%KTTAPasithea Therapeutics-3.43%-4.83%-19.67%-39.68%-85.45%PARNFParnell Pharmaceuticals0.00%0.00%0.00%0.00%+79,900.00%PLRZPolyrizon-3.85%-12.69%-46.00%-99.48%+72,899,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera2.1649 of 5 stars3.53.00.00.02.30.00.6KTTAPasithea Therapeutics0.7974 of 5 stars0.05.00.00.00.01.70.6PARNFParnell PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 3.00Buy$2.75349.35% UpsideKTTAPasithea Therapeutics 0.00N/AN/AN/APARNFParnell Pharmaceuticals 0.00N/AN/AN/APLRZPolyrizon 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PARNF, PLRZ, KTTA, and BFRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BFRIBiofronteraBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $2.75(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$37.32M0.15N/AN/A$0.57 per share1.07KTTAPasithea TherapeuticsN/AN/AN/AN/A$10.60 per shareN/APARNFParnell PharmaceuticalsN/AN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/A$315.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$17.76M-$2.26N/AN/AN/A-30.33%-305.13%-82.67%8/13/2025 (Estimated)KTTAPasithea Therapeutics-$13.90M-$10.60N/A∞N/AN/A-88.14%-81.21%8/12/2025 (Estimated)PARNFParnell PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/APLRZPolyrizon-$1.54MN/A0.00∞N/AN/AN/AN/AN/ALatest PARNF, PLRZ, KTTA, and BFRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BFRIBiofrontera-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million5/15/2025Q1 2025KTTAPasithea TherapeuticsN/A-$1.61N/A-$1.61N/AN/A3/24/2025Q4 2024KTTAPasithea TherapeuticsN/A-$2.41N/A-$2.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/APARNFParnell PharmaceuticalsN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofrontera8.991.400.80KTTAPasithea TherapeuticsN/A3.843.84PARNFParnell PharmaceuticalsN/AN/AN/APLRZPolyrizonN/A10.1610.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%KTTAPasithea Therapeutics23.92%PARNFParnell PharmaceuticalsN/APLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipBFRIBiofrontera1.20%KTTAPasithea Therapeutics16.30%PARNFParnell PharmaceuticalsN/APLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera709.45 million9.33 millionNo DataKTTAPasithea Therapeutics37.44 million6.23 millionNot OptionablePARNFParnell Pharmaceuticals51N/AN/ANot OptionablePLRZPolyrizonN/A5.33 millionN/AN/APARNF, PLRZ, KTTA, and BFRI HeadlinesRecent News About These CompaniesPolyrizon’s nasal drug delivery system shows promising resultsJune 14, 2025 | uk.investing.comPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its ...June 12, 2025 | bakersfield.comPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS TherapeuticsJune 12, 2025 | globenewswire.comPolyrizon Ltd. Receives Nasdaq Notification of Potential Delisting Due to Shareholder Dilution ConcernsMay 23, 2025 | quiverquant.comPolyrizon Announces Receipt of Nasdaq Delisting NoticeMay 23, 2025 | globenewswire.comPolyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025May 22, 2025 | tipranks.comPolyrizon Emerges with Positive Preclinical Data on Nasal Protection PlatformMay 21, 2025 | globenewswire.comPolyrizon Ltd. Announces Increase in Outstanding Shares Following Warrant ExercisesMay 14, 2025 | tipranks.comPolyrizon Ltd.: Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | finanznachrichten.dePolyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | globenewswire.comPolyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail InterestMay 5, 2025 | msn.comPolyrizon reports safety study results for PL-14 Allergy Blocker formulationApril 26, 2025 | markets.businessinsider.comPolyrizon Ltd.: Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | finanznachrichten.dePolyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | globenewswire.comPolyrizon Ltd. Shareholders Approve Key Amendments at Annual MeetingApril 17, 2025 | tipranks.comPolyrizon Faces Nasdaq Compliance ChallengeApril 11, 2025 | tipranks.comPolyrizon Receives Nasdaq Notification Regarding Minimum Bid RequirementsApril 11, 2025 | globenewswire.comPolyrizon entered into agreement with branding, trademark consultancy firmApril 3, 2025 | markets.businessinsider.comPolyrizon Partners with Branding Firm for Strategic Brand DevelopmentApril 2, 2025 | tipranks.comPolyrizon Engages Leading Branding Firm for Strategic Brand DevelopmentApril 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePARNF, PLRZ, KTTA, and BFRI Company DescriptionsBiofrontera NASDAQ:BFRI$0.61 -0.04 (-5.83%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.62 +0.00 (+0.65%) As of 06/20/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Pasithea Therapeutics NASDAQ:KTTA$0.75 -0.03 (-3.43%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.72 -0.03 (-3.48%) As of 06/20/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Parnell Pharmaceuticals OTCMKTS:PARNF$0.08 0.00 (0.00%) As of 04/22/2025Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.Polyrizon NASDAQ:PLRZ$0.73 -0.03 (-3.85%) As of 06/20/2025 04:00 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
